Risk-stratification model to predict progression of monoclonal gammopathy of undetermined significance to myeloma or related disorders.
| Risk Group . | No. of Patients . | Relative Risk . | Absolute Risk of Progression at 20 Years . | Absolute Risk of Progression at 20 Years Accounting for Death as a Competing Risk . |
|---|---|---|---|---|
| This table was originally published in Blood and is reproduced with permission. Rajkumar SV et al., Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) © the American Society of Hematology Blood . 2005 ;106 :812 –817. | ||||
| Low-risk (Serum M protein < 1.5 gm/dL, IgG subtype, normal FLC ratio (0.26–1.65) | 449 | 1 | 5% | 2% |
| Low-Intermediate-risk (Any 1 factor abnormal) | 420 | 5.4 | 21% | 10% |
| High-Intermediate-risk (Any 2 factors abnormal) | 226 | 10.1 | 37% | 18% |
| High-risk (All 3 factors abnormal) | 53 | 20.8 | 58% | 27% |
| Risk Group . | No. of Patients . | Relative Risk . | Absolute Risk of Progression at 20 Years . | Absolute Risk of Progression at 20 Years Accounting for Death as a Competing Risk . |
|---|---|---|---|---|
| This table was originally published in Blood and is reproduced with permission. Rajkumar SV et al., Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) © the American Society of Hematology Blood . 2005 ;106 :812 –817. | ||||
| Low-risk (Serum M protein < 1.5 gm/dL, IgG subtype, normal FLC ratio (0.26–1.65) | 449 | 1 | 5% | 2% |
| Low-Intermediate-risk (Any 1 factor abnormal) | 420 | 5.4 | 21% | 10% |
| High-Intermediate-risk (Any 2 factors abnormal) | 226 | 10.1 | 37% | 18% |
| High-risk (All 3 factors abnormal) | 53 | 20.8 | 58% | 27% |